Pain and Pathological Fractures as Primary Causes of Mobility Impairment in Multiple Myeloma
DOI:
https://doi.org/10.12775/JEHS.2026.88.68186Keywords
multiple myeloma, bone disease, osteolytic lesions, rehabilitation, physical therapy, pathological fracturesAbstract
Background: Multiple myeloma (MM) is a malignant plasma cell disorder frequently complicated by skeletal involvement, affecting up to 80% of patients. Osteolytic lesions, pathological fractures, spinal instability, and chronic pain lead to functional impairment, neurological complications, and reduced quality of life. Bone disease in MM results from an imbalance between bone resorption and formation caused by dysregulation of the RANK/RANKL/OPG pathway.
Aim: To review current literature on bone disease in multiple myeloma with emphasis on functional impairment, rehabilitation, and the role of orthopedic equipment in patient care.
Material and methods: A narrative review was conducted using PubMed, Scopus, Google Scholar, and Polish medical databases. Articles published in English or Polish concerning adult MM patients with skeletal complications were included and analyzed qualitatively.
Results: The literature shows that bone pain and pathological fractures, particularly in the spine, pelvis, ribs, and long bones, are major causes of disability and limited mobility. Pharmacological treatment, radiotherapy, and minimally invasive procedures such as vertebroplasty and kyphoplasty reduce pain and improve stability. Rehabilitation improves muscle strength, balance, and mobility. Orthopedic devices, including spinal orthoses, walkers, and crutches, increase safety and support daily activities.
Conclusion: Skeletal complications remain a significant source of disability in patients with multiple myeloma. A multidisciplinary approach combining pharmacological treatment, interventional procedures, rehabilitation, and orthopedic support is essential to improve functional capacity and quality of life.
References
1. Rymko M, Całbecka M. Plasma cell myeloma with predominant symptoms of bone disease-effective first-line treatment interrupted by low-energy pubic bone fracture: therapy complications management. Case Rep. 2015;6(Suppl A).
2. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33. doi:10.4065/78.1.21
3. Giannopoulos K, Jamroziak K, Usnarska-Zubkiewicz L, et al. Recommendations of the Polish Myeloma Group for the diagnosis and treatment of multiple myeloma 2024/2025. Polish Myeloma Group; 2024
4. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi:10.1002/ajh.25791
5. Giannopoulos K, Jamroziak K, Wróbel T, Dytfeld D. Optimization of treatment in patients with plasma cell myeloma with high cytogenetic risk in Poland. Hematol Clin Pract. 2022;13(2):41–48. doi:10.5603/HCP.a2022.0007
6. Firth J; Medical Masterclass contributors. Haematology: multiple myeloma. Clin Med (Lond). 2019;19(1):58–60. doi:10.7861/clinmedicine.19-1-58
7. Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma: biologic and clinical implications. Cells. 2022;11:2308. doi:10.3390/cells11152308
8. Anderson HC, Reynolds JJ. Pyrophosphate stimulation of calcium uptake into cultured embryonic bones. Fine structure of matrix vesicles and their role in calcification. Dev Biol. 1973;34(2):211–227. doi:10.1016/0012-1606(73)90351-5
9. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539–1543. doi:10.1016/j.ejca.2005.11.037
10. Zdzisińska B, Kandefer-Szerszeń M. The role of RANK/RANKL and OPG in multiple myeloma. Postepy Hig Med Dosw (Online). 2006;60:471–482.
11. Czerwińska-Ledwig O, Szaporów T, Majcher P, Jurczyszyn A. Rehabilitation approaches in patients with multiple myeloma. Przegl Lek. 2018;75(3):136–141.
12. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004;32(2):290–292. doi:10.1016/j.bcmd.2004.01.001
13. De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol. 2004;4(4):340–346. doi:10.1016/j.coph.2004.03.011
14. Zielińska A, Filipowicz-Sosnowska A. Multiple myeloma imitating acute coronary syndrome—diagnostic difficulties. Reumatologia. 2009;47(5):307–309.
15. Giannopoulos K, Dwilewicz-Trojaczek J, Stompór T, et al. Challenges in early diagnosis of multiple myeloma—diagnostic algorithm. Acta Haematol Pol. 2019;50(3):121–129. doi:10.2478/ahp-2019-0020
16. Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP Jr, Epner E. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010;10(6):464–468. doi:10.3816/CLML.2010.n.080
17. Riccardi A, Gobbi PG, Ucci G, Bertoloni D, Luoni R, Rutigliano L, Ascari E. Changing clinical presentation of multiple myeloma. Eur J Cancer. 1991;27(11):1401–1405. doi:10.1016/0277-5379(91)90020-e
18. Nau KC, Lewis WD. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2008;78(7):853–859.
19. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58(23):5294–5297.
20. Jurczyszyn A, Grosicki S, Czerniuk MR, Morga R, Małecki K, Skotnicki AB. Management of multiple myeloma-related bone disease. Przegl Lek. 2013;70(11):950–957.
21. Yeh HS, Berenson JR. Myeloma bone disease and treatment options. Eur J Cancer. 2006;42(11):1554–1563. doi:10.1016/j.ejca.2005.11.035
22. Groeneveldt L, Mein G, Garrod R, Jewell AP, Van Someren K, Stephens R, D'Sa SP, Yong KL. A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC Cancer. 2013;13:31. doi:10.1186/1471-2407-13-31
23. Rome SI, Jenkins BS, Lilleby KE; International Myeloma Foundation Nurse Leadership Board. Mobility and safety in the multiple myeloma survivor: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs. 2011;15(Suppl):41–52. doi:10.1188/11.S1.CJON.41-52
24. Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, Ng AK, Ricardi U, Suh CO, Mauch PM, Specht L, Yahalom J. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101(4):794–808. doi:10.1016/j.ijrobp.2018.05.009
25. Woźniewski M. Rehabilitation of oncology patients—PTOK recommendations. 2014.
26. Gokaraju K, Butler JS, Benton A, Suarez-Huerta ML, Selvadurai S, Molloy S. Multiple myeloma presenting with acute bony spinal cord compression and mechanical instability successfully managed nonoperatively. Spine J. 2016;16(8):e567–e570. doi:10.1016/j.spinee.2016.03.011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ewa Byjoś, Sylwia Buczek, Mateusz Zbylut, Weronika Mstowska, Kamila Milewska, Karolina Bury, Hanna Naliuka, Katarzyna Młynarczyk, Katarzyna Fabiś, Patrycja Mateja
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 3
Number of citations: 0
